![Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior](https://mma.prnewswire.com/media/1222835/SPRAVATO_Logo.jpg?p=facebook)
Janssen Announces U.S. FDA Approval of SPRAVATO® (esketamine) CIII Nasal Spray to Treat Depressive Symptoms in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior
NeuroPsych Wellness Center is accepting new patient inquiries for Spravato (esketamine) Nasal Spray treatment. Spravato is used to treat treatment... | By NeuroPsych Wellness Center, PC | Facebook
![New Spravato FDA Approval Opens The Door to New Patients, Says Sandhya Prashad, M.D. - Sandhya Prashad, MD New Spravato FDA Approval Opens The Door to New Patients, Says Sandhya Prashad, M.D. - Sandhya Prashad, MD](https://sprashadmd.com/wp-content/uploads/2020/08/Spravato-_-Sandhya-Prashad-MD-social-post.png)